Compare Amphastar Pharmaceuticals Inc (AMPH) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Palo Alto Networks Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while Palo Alto Networks Inc trades at $327 (market cap $265.62B). The key difference: Palo Alto Networks Inc is far larger — about 321.5× Amphastar Pharmaceuticals Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | PANW | |
|---|---|---|
Market Cap | $826.08M | $265.62B |
Sector | Health | Technology |
52-Week High | $30.81 | $357.53 |
52-Week Low | $16.87 | $141.67 |
Enterprise Value | $1.22B | $264.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Palo Alto Networks (PANW) trades at $325.91, down 3.67% today, but maintains strong analyst support with 74% buy ratings and a $334.71 consensus target. The stock shows bullish technical signals with support at $321 and resistance at $347. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.85 surpassing the $0.793 estimate. Revenue growth remains robust, climbing from $5.5B in 2022 to $9.22B in 2025, though valuation multiples appear elevated with a P/E of 283.4.
PANW's outlook is supported by AI-driven cybersecurity demand and platformization strategy, but high valuation and competitive pressures present risks. The company's positive cash flow trends and analyst optimism suggest potential upside, though investors should weigh premium pricing against growth sustainability in a dynamic security market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
